A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid Tumors

The objective of the study is to evaluate the safety and tolerability of SI-B037 in participants with locally advanced or metastatic solid tumors.

Trial Details

NCT ID
NCT07940881
Phase
PHASE1
Sponsor
SystImmune Inc.
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • SI-B037
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Signed the informed consent form voluntarily and agreed to follow the trial requirements.
  • Male or Female Age ≥18 years.
  • Has a life expectancy of ≥3 months.
  • Subjects with documented locally advanced or metastatic solid tumor(s) not amenable to curative surgery or radiation and have received at least 1 l…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →